Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
Analysis of exhaled breath condensate biomarkers and cough severity in patients with idiopathic pulmonary fibrosis.
Detailed description
This study will aim to investigate the levels of the reactive oxygen species (ROS) 8-isoprostane in idiopathic pulmonary fibrosis patients' exhaled breath condensate (EBC). EBC samples will be collected using RTube, prior to analysis for levels of 8-isoprostane. An acceptability assessment will be performed for this non-invasive method of EBC collection through a non-validated questionnaire. A regression analysis will then be performed for 8-isoprostane levels against the severity of the patient's cough, assessed through the use of the visual analogue scale for cough (VAS), the King's brief interstitial lung disease questionnaire (KBILD), the Medical Research Council (MRC) dyspnoea scale and the Leicester cough questionnaire. Alongside this an exploratory comparison of cough scores and 8 isoprostane concentration between patients with and without honeycombing and traction bronchiectasis.
Interventions
None listed
Sponsors
University of East Anglia
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female above the age of 40 * IPF diagnosed by a multi-disciplinary team meeting following review of clinical history, thoracic high resolution computed tomography (HRCT) and/or surgical lung according to international guidelines
Exclusion criteria
* A recognised significant co-existing respiratory disease, defined as a respiratory condition that exhibits a clinically relevant effect on respiratory symptoms and disease progression as determined by the principal investigator following multi-disciplinary discussion. For example, patients with bronchiectasis will only be included if the bronchiectasis is deemed to be traction bronchiectasis as a result of idiopathic pulmonary fibrosis * Airflow obstruction defined as a forced expiratory volume at one second over forced vital capacity (FEV1/FVC) \<60% predicted or a residual volume greater than 120% predicted * Significant medical ,surgical or psychiatric disease that in the opinion of the patient's attending physician would exhibit a clinically relevant effect on the patient's health related quality of life * The patient is unable to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 8-isoprostane levels | 1 day (Single measurement ) | Used for detection of 8-isoprostane levels in patients' exhaled breath condensate samples |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Leicester Cough Questionnaire | 1 day (Single measurement ) | Assessment of patient's cough severity |
| Kings brief interstitial lung disease questionnaire | 1 day (Single measurement ) | Assessment of patient's cough severity & exercise tolerance |
| MRC dyspnoea Scale | 1 day (Single measurement ) | Assessment of patient's exercise tolerance |
| Visual analogue scale for Cough | 1 day (Single measurement ) | Assessment of patient's cough severity |
| Non-validated acceptability questionnaire | 1 day (Single measurement ) | Assessment of exhaled breath condensate collection method acceptability |
Countries
United Kingdom
Outcome results
None listed